Susan Margaret Sundström
Corporate Officer/Principal en The University of Southampton .
Perfil
Susan Margaret Sundström is currently a Principal at The University of Southampton.
Previously, she was a Non-Executive Director at Synairgen Plc from 2003 to 2009, and a Non-Executive Director at Karus Therapeutics Ltd.
She also held a position as a Principal at AstraZeneca PLC.
Cargos activos de Susan Margaret Sundström
Empresas | Cargo | Inicio |
---|---|---|
The University of Southampton | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Susan Margaret Sundström.
Empresas | Cargo | Fin |
---|---|---|
SYNAIRGEN PLC | Director/Miembro de la Junta | 03/09/2009 |
ASTRAZENECA PLC | Corporate Officer/Principal | - |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Director/Miembro de la Junta | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
ASTRAZENECA PLC | Health Technology |
SYNAIRGEN PLC | Health Technology |
Empresas privadas | 1 |
---|---|
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Susan Margaret Sundström